About Andrew Ritter
Form D filings for Myosin Therapeutics from 2022 to 2023 list Andrew Ritter as director.
Andrew Ritter first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Andrew Ritter in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Andrew Ritter works with at each company, as listed on that company's latest Form D.
Myosin Therapeutics Inc. · Form D/A, Mar 24, 2023
PD
Patrick Griffin, Ph.D.
Director
DA
Dave Adams
Director
CM
Courtney Miller
President and director
RF
Robert Finizio
Director
TK
Theodore Kamenecka
Director
JS
Jackson Streeter
Director